ETEC

Immuron Announces Positive Results Support Travelan® progress to Phase 3 Clinical Trials in the US

Retrieved on: 
Thursday, March 7, 2024
CHIM, Placebo, USD, Otto, ETEC, Diarrhea, Gastrointestinal tract, Food, Treatment, BLA, Enterotoxigenic Escherichia coli, Bacteria, ASX, Food and Drug Administration, Patient, IMC, Disease, Biologics license application, Infection, Trial of the century, Immuron, Pharmaceutical industry

MELBOURNE, Australia, March 07, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the interim topline results confirming that a single daily dose of Travelan® is effective in prevention of moderate to severe diarrhea following challenge with enterotoxigenic Escherichia coli (ETEC).

Key Points: 
  • This interim analysis summarizes the data for a total of 60 subjects who have completed the inpatient challenge component of this current clinical study.
  • Last patients last visits are anticipated to commence in April this year and final clinical study report will be completed in H2 2024.
  • To learn more about Phase 2 study design, read: U.S. Food and Drug Administration Step 3: Clinical Research
    IMM-124E (Travelan®) will be the first product developed with Immuron’s platform technology to proceed into Phase 3 clinical trials.
  • Immuron is in the process of exploring non-dilutive funding opportunities for these Phase 3 clinical trials.

Desktop Metal and Evonik Expand Partnership, Announce Qualification of Photopolymer on Large Format Additive Manufacturing 2.0 Systems for High-Performance, High-Temperature Products

Retrieved on: 
Tuesday, March 5, 2024
Other Manufacturing, Technology, Chemicals, Plastics, Automotive Manufacturing, Aerospace, Software, Manufacturing, Machine Tools, Metalworking & Metallurgy, Hardware, Electronic Design Automation, DLP, Head, Senior, Multimedia, ETEC, UTS, 3D, Desktop, Polymer, Pro, P12, UV, Conference, Desktop Metal, Metal, Ultimate tensile strength, Plastic, Digital Light Processing, HDT, Extreme, 3D printing

(Photo: Business Wire)

Key Points: 
  • (Photo: Business Wire)
    Evonik INFINAM® ST 6100 L is a benchmark material in high-strength photopolymers for 3D printing.
  • Desktop Metal’s ETEC brand for polymer 3D printing is a leader in Digital Light Processing (DLP) hardware and a carefully curated portfolio of the world’s best AM materials.
  • The ETEC Xtreme 8K offers a build volume of 450 × 371 x 399 mm (17.72 x 14.61 x 15.71 in).
  • The ETEC Pro XL offers a build volume of 249.1 x 140.1 x 165.1 mm (9.8 x 5.5 x 6.5 in).

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Retrieved on: 
Monday, December 4, 2023
ASX, Immuron, Principal, IBS, Diarrhea, NMRC, ETEC, Campylobacter, Disease, IMC, Trial of the century, Johns Hopkins University, MD, Clinical trial, Enterotoxigenic Escherichia coli, Infection, Morale, CIR, CHIM, Gastroenteritis, Safety, JHU, Judgement, Pharmaceutical industry

MELBOURNE, Australia, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce that the US Naval Medical Research Command (NMRC) has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron. The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.

Key Points: 
  • The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter.
  • The clinical study is being led by Principal Investigator Dr Kawsar Talaat, MD at the Johns Hopkins University (JHU) Center for Immunization Research (CIR) Inpatient Unit, located at the JHU Bayview Medical Campus, Baltimore, Maryland.
  • The dosing, challenge and the in-patient stage of the study is anticipated to be completed by the third week of December 2023.
  • The estimated study completion date (last participant, last visit) is June 2024 with headline results from the clinical trial expected to be reported in 2H 2024.

Desktop Metal Announces Third Quarter 2023 Financial Results

Retrieved on: 
Thursday, November 9, 2023
Hardware, Manufacturing, Technology, Machine Tools, Metalworking & Metallurgy, Software, Carbon, Metal, ETEC, Carbon (company), Event, NYSE, Desktop Metal, EBITDA, DLP, DM, GAAP, Phase 10, Deathmatch, Stratasys, Investment, 3D printing, Video game, Bank, Bookkeeping

Desktop Metal, Inc. (NYSE: DM), a global leader in Additive Manufacturing 2.0 technologies for mass production, today announced its financial results for the third quarter ended September 30, 2023.

Key Points: 
  • Desktop Metal, Inc. (NYSE: DM), a global leader in Additive Manufacturing 2.0 technologies for mass production, today announced its financial results for the third quarter ended September 30, 2023.
  • “Revenue in the third quarter was disappointing for Desktop Metal and also for the entire additive manufacturing industry.
  • See “Non-GAAP Financial Information.”
    Desktop Metal will host a conference call on Thursday, November 9, 2023 to discuss third quarter 2023 results.
  • Participants may access the call at 1-877-407-4018, international callers may use 1-201-689-8471, and request to join the Desktop Metal financial results conference call.

Immuron Announces Travelan® Clinical Study Cohort 2 commences

Retrieved on: 
Wednesday, October 18, 2023
ASX, Principal, ETEC, FDA, Trial of the century, Enterotoxigenic Escherichia coli, Morale, Immuron, Diarrhea, Disease, Judgement, CHIM, Clinical trial, Patient, IBS, Safety, Gastroenteritis, IMC, Pharmaceutical industry

MELBOURNE, Australia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company, is pleased to announce the second cohort of 34 participants have commenced the clinical trial to evaluate the efficacy of Travelan® to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

Key Points: 
  • The clinical study is being led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US.
  • The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of Travelan® compared to a placebo in a controlled human infection model (CHIM).
  • The first cohort in-patient stage of the study was completed in August 2023.
  • Immuron received confirmation that a second cohort of 34 study participants were admitted to the Pharmaron inpatient facility and randomized to receive either Travelan® or placebo.

Desktop Metal Launches the ETEC Pro XL — an Industrial Polymer 3D Printer that Drives New Affordability in Premium DLP Technology at Half the Price of its Predecessor

Retrieved on: 
Tuesday, October 10, 2023
Other Manufacturing, Technology, Chemicals, Plastics, Other Technology, Photography, Software, Manufacturing, Machinery, Machine Tools, Metalworking & Metallurgy, Hardware, DLP, Multimedia, NYSE, P4K, BASF, 3D, Printing, EnvisionTEC, ETC, Desktop Metal, ETEC, Jewellery, DM, Metal, Environment, XY, 3D printing, Engineered wood, Reinsurance, Television

View the full release here: https://www.businesswire.com/news/home/20231010116716/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231010116716/en/
    Now available below $40,000, the ETEC Pro XL premium polymer 3D printer delivers extreme accuracy, resolution, and surface finish in a large build area with the high throughput speeds for which area-wide DLP technology is known.
  • ETEC Pro XL is also backwards-compatible with materials previously approved for prior models of the P4K and Perfactory upon request.
  • ETEC Pro XL is a DLP printing system, a form of 3D printing photopolymers that originated in 2002 with the EnvisionTEC Perfactory, the base platform of the ETEC Pro XL.
  • The ETEC Pro XL features a 4K UHD projector powered by an industrial DLP chip below the print vat.

Desktop Metal Launches Live Monitor™ for Users of Additive Manufacturing 2.0 Production Technology

Retrieved on: 
Tuesday, October 3, 2023
Machine Tools, Metalworking & Metallurgy, Semiconductor, Technology, Manufacturing, Telecommunications, Steel, Metal, Ceramic, Arthur Exon, DM, Production system, 3D, ETEC, Web browser, Multimedia, Overall equipment effectiveness, Deathmatch, OEE, Certification, Furnace, Wood, Narrandera Showground Industrial Hall, Live, DNV, AM, NYSE, Sand, Software, 3D printing, Desktop Metal

View the full release here: https://www.businesswire.com/news/home/20231002660898/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20231002660898/en/
    Desktop Metal is launching Live Monitor™, an Industry 4.0 solution for users of select Desktop Metal printers and ancillary equipment to monitor and use real-time data from their equipment to improve efficiency.
  • (Photo: Business Wire)
    Part of the Live Suite™ package of exclusive software offerings from Desktop Metal, Live Monitor provides easy access to system data from any web browser at any time.
  • “At Desktop Metal, we’re committed to driving additive manufacturing into production, and Live Monitor is a vital tool for managing a single productive printing system, such as a Shop System and Furnace, or an entire fleet,” said Ric Fulop, Founder and CEO of Desktop Metal.
  • Desktop Metal (NYSE:DM) is driving Additive Manufacturing 2.0, a new era of on-demand, digital mass production of industrial, medical, and consumer products.

Immuron to present at the Military Health System Research Symposium

Retrieved on: 
Monday, August 14, 2023
Immuron, IMC, Naval Medical Research Center, Enterotoxigenic Escherichia coli, U.S. Department of Defense Strategy for Operating in Cyberspace, Diarrhea, Campylobacter, Gastroenteritis, ETEC, ASX, Traveler, Judgement, Development, IBS, Disease, NMRC, Poster, Morale, MTEC, Pharmaceutical industry

The company will attend the meeting as an Exhibitor and present two posters at the event.

Key Points: 
  • The company will attend the meeting as an Exhibitor and present two posters at the event.
  • One entitled ‘Clinical Evaluation of an Oral prophylactic for prevention of Travelers diarrhea in active-duty military assigned abroad’.
  • The Naval Medical Research Center (NMRC) are also presenting a poster at the symposium on the new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli (ETEC) developed in collaboration with Immuron.
  • The NMRC poster is entitled ‘Research and Development of Hyperimmune Bovine Colostrum Products for the Prevention of Travelers’ Diarrhea’.

Immuron Announces First Patients Enrolled in Travelan® Clinical Study

Retrieved on: 
Tuesday, July 25, 2023
IMC, Enterotoxigenic Escherichia coli, Use of Free and Open-Source Software (FOSS) in the U.S. Department of Defense, Diarrhea, Clinical trial, Gastroenteritis, ETEC, ASX, Judgement, Trial of the century, USU, IBS, Disease, Principal, Morale, FDA, CHIM, Safety, Pharmaceutical industry

MELBOURNE, Australia, July 25, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce the first cohort of 30 participants have been enrolled into the clinical trial to evaluate the efficacy of Travelan® to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli (ETEC).

Key Points: 
  • The clinical study is being led by Principal Investigator Dr Mohamed Al-Ibrahim at the Pharmaron CPC FDA inspected Clinical Research Facility Inpatient Unit located in Baltimore, Maryland US.
  • The Phase 2 clinical trial is designed to evaluate the safety and protective efficacy of Travelan® compared to a placebo in a controlled human infection model (CHIM).
  • The final 30 participants are anticipated to be enrolled into the study and complete the in-patient stage of the study by the end of October 2023.
  • The USU has reported that to date it has successfully enrolled 347 participants into the clinical study following the initiation of enrolment and approximately 260 have completed the study.

3D Printing in Dentistry, 2023 Global Industry Report: Hardware Innovations, Competitive Landscape & Strategies, Future Scenarios Driving Both Growth and Challenges - ResearchAndMarkets.com

Retrieved on: 
Friday, June 30, 2023
Dental, Health, EOS, Shift, Dentures, COVID-19, ETEC, EPlus, Printing, Growth, AM, 3D Systems, Office, DWS, DMG, 3D printing, Dentistry, Formlabs

In 2022 the dental 3D printing market generated $4B in revenue, accounting for nearly one third of the overall additive manufacturing market.

Key Points: 
  • In 2022 the dental 3D printing market generated $4B in revenue, accounting for nearly one third of the overall additive manufacturing market.
  • The seventh edition of '3D Printing in Dentistry' details trends in the broader dental industry that have emerged since the fade of COVID-19 era upheaval, and provides a look into the future of the dental printing market.
  • The study and accompanying market database cover dental printing hardware innovations, competitive landscape and strategies, segmentation of the industry, and future scenarios driving both growth and challenges that will face the litany of current market participants.
  • The 3D Printing in Dentistry is the authoritative market report for additive manufacturing in the dental industry, historically relied upon by global dental companies, 3D printing companies in dental industry, and entrepreneurs and investors.